Podocyte Talk - Dr. Anass Qasem
LightNews LightNews
podocytetalk.bsky.social
Podocyte Talk - Dr. Anass Qasem
@podocytetalk.bsky.social
290 followers 450 following 62 posts
Podocyte Talk is your go-to channel for in-depth discussions on cutting-edge kidney disease research and clinical innovations. Join us weekly as we explore groundbreaking studies, novel therapies, and practical insights into nephrology. #Nephsky
Posts Replies Media Videos
podocytetalk.bsky.social
Dual therapy with finerenone + empagliflozin cut albuminuria by ~30% more than either drug alone in CKD + T2D—with no added safety concerns.
A promising step for combo treatment in DKD.
#CKD #T2D #SGLT2i #Finerenone #CONFIDENCE #Nephrology #BlueskyMD
June 5, 2025 at 3:52 PM
podocytetalk.bsky.social
Simultaneous initiation of SGLT2i, RASi, ns-MRA, and GLP1-RAs presents a promising approach to mitigate the risk of CV events and the progression of kidney disease in patients with CKD.
#podocytetalk #Nephpearls #Nephrology #CKD

journals.lww.com/jasn/abstrac...
May 11, 2025 at 9:07 AM
podocytetalk.bsky.social
Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals.

#podocytetalk #Nephpearls #Nephrology #CKD

journals.lww.com/cjasn/abstra...
May 10, 2025 at 8:47 AM
podocytetalk.bsky.social
In a diverse IgAN cohort, 36% reached kidney failure, major eGFR decline, or died within 2.7 years. Proteinuria ≥0.5 g/g strongly predicted poor outcomes, challenging past beliefs that <1 g/g is low risk.

#podocytetalk #Nephpearls #Nephrology #CKD #nephsky

academic.oup.com/ndt/advance-...
May 5, 2025 at 8:19 AM
podocytetalk.bsky.social
Kidney outcomes were poor in genetic nephrotic syndrome; in FSGS outcomes were strongly associated with proteinuria level. MCD patients had better proteinuria control than FSGS and had better outcomes at each proteinuria level.
#podocytetalk #Nephpearls #nephsky

journals.lww.com/jasn/abstrac...
May 4, 2025 at 5:24 PM
podocytetalk.bsky.social
Among low-risk patients undergoing PCI, contrast-associated AKI was rare, and withholding or continuing SGLT2 inhibitors had no impact on AKI risk or renal function. discontinuation in this setting may not be necessary.

journals.lww.com/kidney360/pa...
#Podocytetalk @asnpublications.bsky.social
March 28, 2025 at 7:09 PM
podocytetalk.bsky.social
This study highlights the negative impact of hypertension early after kidney transplantation and emphasizes the importance of effective treatment to improve long-term graft and patient survival.

www.kireports.org/article/S246...

#Podocytetalk #nephrology #CKD #Nephsky
March 28, 2025 at 7:04 PM
podocytetalk.bsky.social
A JASN study links higher CKM stages to increased 15-year CV mortality (Stage 0: 5.5%, Stage 4: 15.2%). Stage 4 had a 9.6% higher risk. Early intervention is crucial.

journals.lww.com/jasn/pages/a...

#Podocytetalk #Nephrology #CKM
March 16, 2025 at 12:19 PM
podocytetalk.bsky.social
High-intensity interval training significantly reduced the risk of rapid eGFR decline in older adults.

journals.lww.com/jasn/abstrac...

#podocytetalk #Nephpearls #CKD #nephsky
February 25, 2025 at 4:01 AM
podocytetalk.bsky.social
No association was observed between aspirin use and risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding.

journals.lww.com/cjasn/abstra...

#podocytetalk #CKD #nephsky
February 4, 2025 at 4:42 AM
podocytetalk.bsky.social
In people with non–dialysis-dependent CKD, revascularization may be associated with lower all-cause mortality compared with medical management and may also lower the risk of cardiovascular events.

journals.lww.com/cjasn/pages/...

#podocytetalk #Nephpearls #CKD #nephsky
February 4, 2025 at 4:38 AM
podocytetalk.bsky.social
These findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or polypharmacy.

CJASN 19(9):p 1119-1129, September 2024

#podocytetalk #Nephpearls #CKD #nephsky

journals.lww.com/cjasn/fullte...
February 2, 2025 at 3:36 PM
podocytetalk.bsky.social
In patients with CKD included in this MINT subgroup analysis, a liberal transfusion strategy was not worse than a restrictive transfusion strategy and was associated with less harm in subgroups not receiving dialysis.

journals.lww.com/jasn/abstrac...

#podocytetalk #Nephpearls #CKD
February 1, 2025 at 5:50 PM
podocytetalk.bsky.social
Greater attention should be given to RV and LA dysfunction for early identification of cardiac dysfunction in CKD patients.

Nephrology Dialysis Transplantation 04 October 2024
doi.org/10.1093/ndt/...

#podocytetalk #Nephpearls #CKD #nephsky
February 1, 2025 at 5:57 AM
podocytetalk.bsky.social
LYFT updated for older kidney transplant candidates; transplant still better than dialysis (5-year LYFT). Trends slightly declined; needs nuanced metrics for policy.

#podocytetalk #Nephpearls #CKD #nephsky
February 1, 2025 at 5:49 AM
podocytetalk.bsky.social
Vadadustat once daily, but not three times weekly, was noninferior to DA in the correction and maintenance of hemoglobin in patients with dialysis-dependent CKD converted from an ESA.

Kidney360 5(11):p 1652-1661, November 2024. | DOI: 10.34067/KID.0000000567

#podocytetalk #nephsky #nephrology
January 15, 2025 at 6:54 PM
podocytetalk.bsky.social
Compared with initiation of antiemetics with lesser QT-prolonging potential, initiation of ondansetron was associated with higher short-term cardiac risks among people receiving hemodialysis.

JASN 35(6):p 761-771, June 2024. | DOI: 10.1681/ASN.0000000000000336

#podocytetalk #nephsky #nephrology
January 15, 2025 at 6:50 PM
podocytetalk.bsky.social
Restarting RASi after discontinuation was associated with a lower risk of kidney outcomes and mortality but not related to the incidence of hyperkalemia.

Journal of the American Society of Nephrology 35(10):p 1391-1401, October 2024. | DOI: 10.1681/ASN.0000000000000425

#podocytetalk #nephsky
January 14, 2025 at 5:17 PM
podocytetalk.bsky.social
SGLT2 inhibitors (SGLT2i) consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels in individuals with type 2 diabetes (T2D), CKD, & heart failure.

Clin J Am Soc Nephrol. 2025 Jan 1;20(1):39-49.
doi: 10.2215/CJN.0000000000000568.

#podocytetalk #nephsky #nephrology
January 14, 2025 at 5:11 PM
podocytetalk.bsky.social
SGLT2 inhibitor and GLP-1 RA discontinuation was common and associated with harmful outcomes in adults with CKD.

Journal of the American Society of Nephrology 36(1):p 87-98, January 2025. | DOI: 10.1681/ASN.0000000000000477

#podocytetalk #Nephpearls #Nephrology #CKD
January 14, 2025 at 3:56 AM